NovaBridge Biosciences
NBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $69 | $1,122 | $2,379 | $22,858 |
| - Cash | $68 | $2,141 | $3,214 | $3,524 |
| + Debt | $4 | $134 | $38 | $112 |
| Enterprise Value | $5 | -$886 | -$797 | $19,447 |
| Revenue | $0 | $4 | -$11 | $88 |
| % Growth | -100% | 141.9% | -112.2% | – |
| Gross Profit | $0 | $4 | -$249 | $42 |
| % Margin | – | 100% | 2,325.8% | 47.3% |
| EBITDA | -$373 | -$344 | -$51 | -$2,058 |
| % Margin | – | -7,674.2% | 478.9% | -2,337.4% |
| Net Income | -$162 | -$1,466 | -$2,507 | -$2,332 |
| % Margin | – | -32,674% | 23,438.9% | -2,648.7% |
| EPS Diluted | -4.46 | -17.62 | -30.38 | -30.68 |
| % Growth | 74.7% | 42% | 1% | – |
| Operating Cash Flow | -$53 | -$73 | -$1,103 | -$973 |
| Capital Expenditures | -$0 | -$0 | -$46 | -$30 |
| Free Cash Flow | -$53 | -$73 | -$1,149 | -$1,003 |